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The results of screening of 2-(benzoyilamino)(1-R-2-oxoindolin-3-ylidene)acetic acid derivatives on 
the antihypoxic activity are presented in the article. It has been determined that under the conditions 
of acute hypоbaric hypoxia compounds 4, 14 and 15 have shown the increase of the integral index 
of the antihypoxic activity of substances – the overall lifetime of animals at the “high-altitude plateau”. 
However, the mortality rate of animals reached 20% for compound 4, and it signiﬁ cantly exceeded 
the control data. At the same time, compound 14 by its antihypoxic activity signiﬁ cantly increased the
overall lifetime of animals by 150% compared to the control data, but its effect was signiﬁ cantly weaker
than the effect of the reference drug mexidol, which increased the lifetime of animals by 197% (p<0.05). For
compound 15 the overall lifetime of animals increased by 186% compared to the control data (p<0.05) 
and did not differ signiﬁ cantly from that of the reference drug. The data obtained indicate that most 
of the substances studied – derivatives of 2-(benzoyilamino)(1-R-2-oxoindolin-3-ylidene)acetic acid – 
demonstrate certain antihypoxic properties, as well as derivatives of 2-(2-oxoindolin-3-ylidene)acetic 
acid previously researched. Moreover, only compound 15 corresponds to the antihypoxic efﬁ cacy of 
the reference drug, and by the index of recovery of the animals’ physical activity after their staying at 
the “high-altitude plateau” (the posture recovery time) it exceeds the effect of the antihypoxant drug 
mexidol.
Hypoxia is a pathological condition that occurs when
there is an insufﬁ cient supply of oxygen to tissues or dis-
order of oxygen uptake during the process of oxidation.
It occurs under the conditions of oxygen deﬁ ciency in 
the environment, and as a result of various pathological
processes and diseases associated with disorders of the
respiratory and cardiovascular systems, the blood trans-
port function or metabolism [1, 4]. In addition, very high
“hypoxic risk” is related to certain professions, such as 
pilots, astronauts, mountaineers, alpine tourists, divers 
and submariners, i.e. such working conditions that are 
associated with the low partial pressure of oxygen in the
inhaled air. In everyday life people are inﬂ uenced by the
physiological hypoxia. Under the physiological condi-
tions hypoxia develops during an intense muscular work, 
mental activity, signiﬁ cantly enhanced physiological acti-
vity of the liver, kidneys and gastrointestinal tract, fe-
tal development and in old age. Consequently, practical 
medicine regularly faces the problem of protecting the 
body from complications arising from oxygen deﬁ cien-
cy [9]. In this regard, drugs affecting the metabolism du-
ring hypoxia – antihypoxants, which are agents that im-
prove oxygen consumption by the body and reduce oxy-
gen demand of tissues and organs, thereby increasing the
body’s resistance to oxygen deﬁ ciency, are of particular 
interest. A wide choice of medicines with the antihypoxic 
activity is presented at the pharmaceutical market of Uk-
raine; mexidol is considered to be one of the most active 
and widely used drugs [3, 7], however, in many cases 
its action is not sufﬁ ciently effective. Thus, the search 
and introduction of new effective antihypoxants into cli-
nical practice is a topical issue of medicine and pharmacy.
The aim of the current study was to conduct scree-
ning of the antihypoxic activity among 2-(benzoyilami-
no)(1-R-2-oxoindolin-3-ylidene)acetic acid derivatives 
under the conditions of acute hypobaric hypoxia.
Materials and Methods
24 Biologically active substances (BAS) – derivatives
of 2-(benzoyilamino)(1-R-2-oxoindolin-3-ylidene)ace-
tic acid – synthesized at the Department of Analytical 
Chemistry of the National University of Pharmacy by 
professor S.V.Kolisnyk were selected for study (Fig.). 
Fig. The structural formula of 2-(benzoyilamino)(1-R-2-oxoindolin-3-
ylidene)acetic acid derivatives (compounds 1-24).
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2-(Benzoyilamino)(1-R-2-oxoindolin-3-ylidene) ace-
tic acids (compounds 1-4), and their phenyl- (compounds 
5-11), naphthalen- (compounds 12-14) phenethyl- (com-
pounds 15-17), hydroxynaphthalenamides (compounds 23-24)
and ethyl esters of N-[2-(benzoyilamino) (2-oxoindolin-
3-ylidene)acetyl]glycine (compounds 18-22) were studied.
The animals were kept under the standard vivarium 
conditions at a constant temperature and humidity with 
free access to food and water. All manipulations were 
carried out in accordance with the European Union Di-
rective 2010/63/EU on the protection of animals used for
scientiﬁ c purposes. 
The research was conducted under the conditions of 
acute hypoxia on 156 nonlinear white mature male rats 
weighing 180-200 g aged 3 months and moderately resis-
tant to hypoxia. The resistance of animals to hypoxia was
determined 2 weeks prior to the research by the known 
method [2]. Acute hypobaric hypoxia was simulated in 
the modiﬁ ed ﬂ ow pressure chamber by imitation of the 
lifting of rats to an altitude of 12000 metres. “Ascent” 
and “descent” of animals were carried out at a speed of 
50 m/s. At the “high-altitude plateau” rats were main-
tained until the second agonal inspiration, and then the 
“descent” to the previous zero altitude was performed 
[11]. The substances studied were administered intrape-
ritoneally 35 min before hypoxia modelling in the dose 
of 15 mg/kg in the form of an aqueous suspension sta-
bilized by polysorbate 80 (Tween 80) (AppliChem GmbH, 
Germany) [6, 8]. The reference drug – antihypoxant me-
xidol (ethylmethylhydroxypyridine succinate) was ad-
ministered in the dose of 100 mg/kg [10]. The animals 
of the control group were injected with an equivalent 
amount of an aqueous suspension with polysorbate 80. 
Doses of substances were selected according to the pub-
lished data concerning the antihypoxic activity in expe-
rimental studies.
The antihypoxic activity of substances was assessed by
the animals’ survival indices at the “high-altitude plateau”:
the time of the posture loss; the lifetime – the time till 
the second agonal inspiration; the posture recovery time
after termination of hypoxia and a gradual return of ani-
mals to the previous zero altitude; and the overall life-
time of animals – summation of the time of the posture 
loss and the lifetime [5].
Table 1
" e life parameters of rats with acute hypobaric hypoxia of the critical level and when introducing 
2-(benzoyilamino)(1-R-2-oxoindolin-3-ylidene)acetic acid derivatives and mexidol (M±m, n=6)
Group Time of the posture loss, s
The lifetime till the second 
agonal inspiration, s
Time of the posture 
recovery, s
Control 64.9±9.6 15.3±8.3 398.8±9.2
Mexidol 132.8±5.8* 25.6±8.6* 225.3±9.4*
Compound 1 66.7±4.7 25.0±3.2* 244.7±5.8*
Compound 2 43.8±10.7 15.0±2.5 654.0±7.4*/**
Compound 3 31.5±11.4 19.7±11.8 295.0±13.4*
Compound 4 131.3±18.7* 27.5±12.5 363.2±14.4
Compound 5 60.0±10.6 14.0±5.2 240.0±10.9*
Compound 6 57.5±7.8 27.5±5.2 263.6±6.9*
Compound 7 19.4±10.4* 9.6±7.2 333.0±10.0
Compound 8 23.0±5.9 9.2±8.3 257.3±4.2*
Compound 9 42.5±7.8 51.3±3.9*/** 278.2±6.2*
Compound 10 23.0±10.5 28.0±9.8 264.2±10.0*
Compound 11 27.5±4.3 12.8±5.8 215.4±6.3*
Compound 12 39.0±10.3 29.2±9.2 310.8±7.5*
Compound 13 23.0±9.5 14.0±10.3 205.2±8.8*
Compound 14 69.5±8.2 51.4±7.6*/** 265.4±5.7*
Compound 15 126.0±10.5* 23.5±5.7* 146.3±8.5*/**
Compound 16 13.4±8.4* 17.4±9.3 262.5±7.4*
Compound 17 15.5±5.4* 9.8±3.8 312.8±4.2*
Compound 18 61.0±6.7 37.8±4.8* 241.0±10.6*
Compound 19 52.2±9.3 24.4±7.3 308.0±10.7*
Compound 20 25.2±4.8 19.0±5.2 276.2±9.4*
Compound 21 53.8±7.4 17.4±6.4 289.8±9.7*
Compound 22 19.8±3.9* 3.0±0.5* 345.8±9.4
Compound 23 65.0±7.4 42.0±4.6* 341.4±8.7
Compound 24 70.0±6.5 28.0±7.5 309.8±7.3*
Note: * – signi; cance compared to the control (p<0.05); ** – signi; cance compared to mexidol (p<0.05).
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Statistical analysis of the results was performed using
SPSS Statistics 17.0 and Microsoft Excel 2013 software.
Statistical signiﬁ cance was assessed using parametric Stu-
dent’s t-test (for normal distribution) and non-paramet-
ric Mann-Whitney U-test (in case of non-normal distri-
bution). The critical level of signiﬁ cance was accepted 
as p≤0.05.
Results and Discussion
The results of the antihypoxic activity screening of 
the compounds studied compared to the control group 
and the action of the reference drug mexidol are presen-
ted in Tab. 1. 
Analysis of screening 2-(benzoyilamino)(1-R-2-oxo-
indolin-3-ylidene)acetic acid derivatives have shown that
the most signiﬁ cant prolongation of life parameters in 
acute hypobaric hypoxia of the critical level according
to the highest index of the lifetime at the “high-altitude
plateau” after the loss of posture till the second agonal
inspiration (p<0.05) have animals treated with compo-
unds 1, 4, 9, 14, 15, 18, 23 and 24 (Tab. 1). The highest
index of the time of the posture loss at the “high-alti-
tude plateau” was for 2-(benzoyilamino)(1-propyl-2-oxo-
indolin-3-ylidene)acetic acid (compound 4) and for phe-
nylethylamide 2-(benzoyilamino)(1-methyl-2-oxoindolin-
3-ylidene)acetic acid (compound 15), it exceeded the cont-
rol data by 2 and 1.9 times (p<0.05), respectively. The 
index of the posture recovery time after the beginning of 
the “descent” of animals from the “high-altitude plateau” 
was signiﬁ cantly lower compared to the control data for 
almost all BAS under research except compounds 2, 4, 
7, 22, 23. In the group of phenylethylamide 15 this index
was the lowest, and it signiﬁ cantly exceeded the antihypo-
xic efﬁ cacy of the reference drug mexidol by 1.5 times. 
After administration of compounds 4, 9, 18, 23 and 
24 such adverse reactions as convulsions and cyanosis of 
the skin and mucous membranes were observed. It was
also found that among substances exhibiting the signi-
ﬁ cant antihypoxic activity only compounds 14 and 15 
did not cause any external signs of side effects after their 
administration when modelling hypoxia. 
Compounds 4, 14 and 15 demonstrated the increase
of the integral index of the antihypoxic activity of sub-
stances – the overall lifetime of animals at the “high-al-
titude plateau” (Tab. 2). However, the mortality rate of 
animals reached 20% for compound 4, and it signiﬁ cantly
exceeded the control data. At the same time, amide 14 by 
its antihypoxic activity signiﬁ cantly increased the ove-
rall lifetime of animals by 150% compared to the cont-
rol data, but its effect was signiﬁ cantly weaker than the 
effect of the reference drug mexidol, which increased the
lifetime of animals by 197% (p<0.05). For compound 15
the overall lifetime of animals increased by 186% com-
pared to the control data (p<0.05) and did not differ sig-
niﬁ cantly from that of the reference drug. 
The data obtained indicate that most of the substances
studied – derivatives of 2-(benzoyilamino)(1-R-2-oxo-
indolin-3-ylidene)acetic acid – demonstrate certain anti-
hypoxic properties, as well as derivatives of 2-(2-oxoin-
dolin-3-ylidene)acetic acid previously researched [8]. Mo-
reover, only compound 15 corresponds to the antihypoxic
efﬁ cacy of the reference drug, and by the index of reco-
very of the animals’ physical activity after their staying 
at the “high-altitude plateau” (the posture recovery time)
it exceeds the effect of the antihypoxant drug mexidol.
CONCLUSIONS
1. The results of screening have shown that deriva-
tives of 2-(benzoyilamino)(1-R-2-oxoindolin-3-ylidene)
acetic acid are a promising class of compounds for crea-
ting antihypoxic medicines on their basis, and it is the 
basis for further pre-clinical studies of pharmacological 
properties of these compounds.
2. Compound 15 corresponds to the action of the re-
ference drug mexidol by its antihypoxic activity, and sig-
niﬁ cantly exceeds its effect by the index of recovery of
the physical activity after the animals’ staying at the “high-
altitude plateau”.
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Mexidol 158.4±14.4* 197 100
Compound 4 158.8±31.2* 198 100
Compound 14 120.9±15.8*/** 150 76
Compound 15 149.5±16.2* 186 94
Note: * – signi; cance compared to the control (p<0.05); 
** – signi; cance compared to mexidol (p<0.05).
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СКРИНІНГ ПОХІДНИХ 2-(БЕНЗОЇЛАМІНО)(1-R-2-ОКСОІНДОЛІН-3-ІЛІДЕН)ОЦТОВОЇ 
КИСЛОТИ ПРИ ГОСТРІЙ ГІПОБАРИЧНІЙ ГІПОКСІЇ
І.І.Заморський, Ю.С.Букатару, Е.Л.Ленга, С.В.Колісник, О.О.Алтухов 
Ключові слова: антигіпоксанти; гіпобарична гіпоксія; 
похідні 2-(бензоїламіно)(1-R-2-оксоіндолін-3-іліден)оцтової кислоти; мексидол
Наведені результати скринінгу похідних 2-(бензоїламіно)(1-R-2-оксоіндолін-3-іліден)оцтової 
кислоти на антигіпоксантну активність. Встановлено, що за умов гострої гіпобаричної гі-
поксії збільшення інтегрального показника антигіпоксантної активності речовин – загаль-
ний час життя тварин на «висотному плато» – демонстрували речовини під номерами 4, 14 
і 15. Проте для речовини 4 рівень смертності тварин при проведенні досліджень становив 
20%, що значно перевищувало контрольні дані. При цьому сполука під номером 14 за анти-
гіпоксантною активністю достовірно збільшувала загальну тривалість життя тварин на 
150% щодо даних контролю, але вірогідно поступалась препарату порівняння мексидолу: цей 
лікарський засіб збільшував час життя тварин на 197% (р<0,05). Для речовини під номером 
15 загальна тривалість життя тварин зростала на 186% у порівнянні з даними контролю 
(р<0,05) і вірогідно не відрізнялася від показників референс-препарату. Отримані дані вказу-
ють на те, що більшість досліджуваних речовин, похідних 2-(бензоїламіно)(1-R-2-оксоіндолін-
3-іліден)оцтової кислоти проявляють певні антигіпоксантні властивості. Водночас тільки 
речовина за номером 15 не поступається за антигіпоксантною ефективністю дії препара-
ту порівняння, а за показником відновлення фізичної активності тварин після їх перебування 
на «висотному плато» (часом відновлення пози) перевершує дію відомого антигіпоксанта 
мексидолу.
СКРИНИНГ ПРОИЗВОДНЫХ 2-(БЕНЗОИЛАМИНО)(1-R-2-ОКСОИНДОЛИН-3-ИЛИДЕН)
УКСУСНОЙ КИСЛОТЫ ПРИ ОСТРОЙ ГИПОБАРИЧЕСКОЙ ГИПОКСИИ
И.И.Заморский, Ю.С.Букатару, Э.Л.Ленга, С.В.Колесник, А.А.Алтухов 
Ключевые слова: антигипоксанты; гипобарическая гипоксия; производные 
2-(бензоиламино)(1-R-2-оксоиндолин-3-илиден)уксусной кислоты; мексидол
Приведены результаты скрининга производных 2-(бензоиламино)(1-R-2-оксоиндолин-3-илиден)
уксусной кислоты на антигипоксантную активность. Установлено, что в условиях острой 
гипобарической гипоксии увеличение интегрального показателя антигипоксантной актив-
ности веществ – общее время жизни животных на «высотном плато» – демонстрировали 
вещества под номерами 4, 14 и 15. Однако, для вещества 4 уровень смертности живот-
ных при проведении исследований составил 20%, что значительно превышало контрольные 
данные. При этом соединение под номером 14 по антигипоксантной активности достовер-
но увеличивало общую продолжительность жизни животных на 150% относительно данных 
контроля, но достоверно уступало препарату сравнения мексидолу: это лекарственное 
средство увеличивало время жизни животных на 197% (р<0,05). Для вещества под номе-
ром 15 общая продолжительность жизни животных возрастала на 186% по сравнению с 
данными контроля (р<0,05) и достоверно не отличалась от показателей референс-пре-
парата. Полученные данные указывают на то, что большинство исследуемых веществ, про-
изводных 2-(бензоиламино)(1-R-2-оксоиндолин-3-илиден)уксусной кислоты проявляют опре-
деленные антигипоксантные свойства. В то же время только вещество под номером 15 
не уступает по антигипоксантной эффективности действию препарата сравнения, а по 
показателю восстановления физической активности животных после их пребывания на 
«высотном плато» (время восстановления позы) превосходит действие известного анти-
гипоксанта мексидола.
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